32 results about "Mucosa disease" patented technology

The immunoglobulins of the present invention are useful therapeutic immunoglobulins against mucosal pathogens such as S. mutans. The immunoglobulins contain a protection protein that protects the immunoglobulins in the mucosal environment. The invention also includes the greatly improved method of producing immunoglobulins in plants by producing the protection protein in the same cell as the other components of the immunoglobulins. The components of the immunoglobulin are assembled at a much improved efficiency. The method of the invention allows the assembly and high efficiency production of such complex molecules. The invention also contemplates the production of immunoglobulins containing protection proteins in a variety of cells, including plant cells, that can be selected for useful additional properties. The use of immunoglobulins containing protection proteins as therapeutic antibodies against mucosal and other pathogens is also contemplated.

A topical composition comprises a clay material with a negative surface charge; magnesium ions and calcium ions; water and / or a non-aqueous solvent; and a substantially non-cationic carrier. The mean particle size of the clay material is at least 5 nm, and the total molar amount of magnesium ions is higher than the total molar amount of calcium ions. The composition is suitable for the prophylaxis and treatment of skin diseases, skin conditions, or mucosal diseases.

An immunomodulatory compound is utilized to treat mucosa disease.

The invention relates to drugs for treating mouth mucosa diseases and the manufacture field of the drugs for treating mouth mucosa diseases, in particular to a mouth mucosa drug sustained release preparation for treating a mouth periodontal disease by doxycycline. The preparation is composed of a mouth mucosa contacted layer and a non-adhesiveness sealing layer. The mouth mucosa contacted layer comprises, by weight, 2-20 / 80-98 of antibiotic drugs and auxiliary materials. The components of the non-adhesiveness sealing layer are non-adhesiveness low water-solubility high-molecular polymers. The non-adhesiveness low water-solubility high-molecular polymers are chosen from polyvinyl alcohol. The components of mouth mucosa drug sustained release preparation comprise 2.0g of methyl vinyl ether-maleic anhydride copolymers, 2.0g of polyoxyethylene, 2.0g of carboxymethyl cellulose sodium, 12.0g of natural starch, 2.0g of menthol and 0.5g of doxycycline, and the rest is poval. The mouth mucosa drug sustained release preparation has the advantages that drug delivering is convenient, drug releasing time is long, drug releasing speed is even, targeting is strong, and adhesive force with mucosas is strong. In addition, the manufacturing method is simple in operation, low in cost, environment-friendly and suitable for industrial production.

The invention relates to an externally-applied medicine for treating skin and mucosa disease caused by human papilloma virus, which is prepared from Chinese medicinal herbs including cnidium fruit, dysosmapleiantha woods, brucea fruit, poria cocos, cordate houttuynia, flavescent sophora root and wasp's nest. The preferred dosage form of the preparation is soft electuary.

Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholinereceptor (nAChR) agonist, such as (S)-(l-methyl-2- pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

The invention provides a traditional Chinese medicinal composition for treating infantile diaper rash and a preparation method of the traditional Chinese medicinal composition. The preparation method comprises the following steps: grinding 35-45 parts of calcined gypsum into superfine powder, grinding 3-7 parts of borneol into fine powder, heating and dissolving 5-15 parts of beeswax, 35-45 parts of sesame oil and 3-7 parts of lanolin, filtering and cooling to about 65-70 DEG C; adding the borneol fine powder and dissolving the borneol fine powder, then adding the calcined gypsum superfine powder, completely stirring uniformly to be semi-solidified so as to obtain the traditional Chinese medicinal composition in ointment form. The traditional Chinese medicinal composition disclosed by the invention is used for treating infantile diaper rash caused by accumulation of damp heat, and the composition is adaptive to such fundamental symptoms as skin flushing, swelling, rash, vesicle, drainage, diabrosis and the like; and meanwhile, the traditional Chinese medicinal composition also has a relatively good treatment effect on skin mucosa diseases including inflammatory hemorrhoid, anal fissure, bedsore, herpes zoster, mosquito bite and the like.

Methods of treating and preventing conditions of a nasal or paranasal mucous membrane are described. The methods include administering a pharmaceutical composition including a nicotinic acetylcholine receptor (nAChR) agonist, such as (S)-(1-methyl-2-pyrrolidinyl)-pyridine, or a pharmaceutically acceptable salt, analog, precursor or derivative thereof. The methods can be used to treat a wide variety of conditions of the nasal or paranasal mucous membrane, such as nasal congestion and nose bleeds.

The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: E. coli) and fungi (b: Pathogen yeast and c: Penicillium).a) Escherichia coli (additionally silver (“Ag”) as control),b) Candida parapsilosis, c) Penicillium notatum.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine compound preparation used for preventing recurrent aphthae and application thereof, wherein the traditional Chinese medicine compound preparation is prepared by using Chinese medicines as raw materials. The preparation comprises the following Chinese medicinal herbs in parts by weight: 1-3 parts of rhizome coptisdis, 8-10 parts of capejasmine, 8-10 parts of cortex moutan, 8-10 parts of radix ophiopogonis, 4-6 parts of rhizome cimicifugae, 12-15 parts of rhizome phragmitis and 8-10 parts of raw cattail pollen. The preparation used for preventing recurrent aphthae can be used for treating mouth mucosa diseases, such as oral erosive lichen planus (OLP), chronic glossitis, glossopyrosis syndrome, behcet's diseases and chronic gingivitis.

The invention relates to a pharmaceutical composite which inhibits and / or relieves pruritus caused by dermatosis, mucosa disease or systemic disease or lesion, and is made from derivatives, salt or solvate of phenyl butyric acid and short chain fatty acid with effective dose and a carrier which is acceptable pharmaceutically.

The invention provides a pharmaceutical composition for treating oral periodontal and mucosal diseases, which is prepared from raw materials in the following weight proportions: 5-60 parts of turmeric, 3-30 parts of Coptidis Rhizoma, 10-60 parts of Angelica dahurica . The invention further discloses the preparation method and application of the pharmaceutical composition. The pharmaceutical composition of the invention has good therapeutic effects on oral periodontal and mucosal diseases such as periodontitis, oral striae diseases, oral lichen planus and the like. The pharmaceutical composition of the present invention has the advantages of novel formula, simple composition, low cost, significant curative effect, no toxic and side effects, and not easy to produce tolerance, etc., and provides clinical treatment for patients with periodontitis, oral striae diseases, oral lichen planus, and oral leukoplakia. a new drug option.

The invention discloses magnetic gel for assisting endoscopic mucosal dissection. The magnetic gel is prepared mainly from permanent magnetic material microparticles, a sodium alginate solution and acalcium chloride solution, and medical dye can also be added; a preparation method thereof comprises the following steps: preparing the sodium alginate solution, adding the permanent magnetic materialmicroparticles, uniformly mixing to obtain a solution A, and using the calcium chloride solution or a mixed solution of the calcium chloride solution and the medical dye as a solution B; filling a double-cavity synchronous injection device with the solution A and the solution B respectively, and injecting an appropriate amount of an uniformly mixed solution into a mucosal lesion to be dissected according to the size of the lesion during using, wherein the uniformly mixed solution can form the magnetic gel in the lesion within a short time. The application system comprises the double-cavity synchronous injection device for injecting the uniformly mixed solution into the mucosal lesion to be dissected, and a detachable magnetic ring at the head end of an endoscope, wherein the uniformly mixed solution forms the magnetic gel after injection. Through magnetic attraction between the magnetic gel and the detachable magnetic ring at the head end of the endoscope, a pulling force opposite toa muscular layer is provided, so that the dissection between mucosa and muscular layer is facilitated; the invention has the advantages of convenience in operation, reduction in surgical difficulty and the like.